189 related articles for article (PubMed ID: 26678404)
1. Can a Benefit be Expected from Surgical Debulking of Unresectable Pseudomyxoma Peritonei?
Delhorme JB; Elias D; Varatharajah S; Benhaim L; Dumont F; Honoré C; Goéré D
Ann Surg Oncol; 2016 May; 23(5):1618-24. PubMed ID: 26678404
[TBL] [Abstract][Full Text] [Related]
2. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Chua TC; Moran BJ; Sugarbaker PH; Levine EA; Glehen O; Gilly FN; Baratti D; Deraco M; Elias D; Sardi A; Liauw W; Yan TD; Barrios P; Gómez Portilla A; de Hingh IH; Ceelen WP; Pelz JO; Piso P; González-Moreno S; Van Der Speeten K; Morris DL
J Clin Oncol; 2012 Jul; 30(20):2449-56. PubMed ID: 22614976
[TBL] [Abstract][Full Text] [Related]
3. Huge pseudomyxoma peritonei: Surgical strategies and procedures to employ to optimize the rate of complete cytoreductive surgery.
Benhaim L; Honoré C; Goéré D; Delhorme JB; Elias D
Eur J Surg Oncol; 2016 Apr; 42(4):552-7. PubMed ID: 26868165
[TBL] [Abstract][Full Text] [Related]
4. Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience.
Vaira M; Cioppa T; DE Marco G; Bing C; D'Amico S; D'Alessandro M; Fiorentini G; DE Simone M
In Vivo; 2009; 23(4):639-44. PubMed ID: 19567401
[TBL] [Abstract][Full Text] [Related]
5. Complete Cytoreductive Surgery vs. Debulking Surgery for pseudomyxoma peritonei of appendiceal origin: A propensity score-matched study based on a single-center experience.
Ma R; Lu D; Wang B; Zhai X; Xia A; An L; Shi G; Cai Y; Lu Y; Pang S; Chen F; Xu H
Eur J Surg Oncol; 2021 Sep; 47(9):2369-2376. PubMed ID: 34034942
[TBL] [Abstract][Full Text] [Related]
6. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei of appendicular and extra-appendicular origin.
Delhorme JB; Severac F; Averous G; Glehen O; Passot G; Bakrin N; Marchal F; Pocard M; Lo Dico R; Eveno C; Carrere S; Sgarbura O; Quenet F; Ferron G; Goéré D; Brigand C;
Br J Surg; 2018 May; 105(6):668-676. PubMed ID: 29412465
[TBL] [Abstract][Full Text] [Related]
7. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
Baratti D; Kusamura S; Nonaka D; Langer M; Andreola S; Favaro M; Gavazzi C; Laterza B; Deraco M
Ann Surg Oncol; 2008 Feb; 15(2):526-34. PubMed ID: 18043976
[TBL] [Abstract][Full Text] [Related]
8. Complete cytoreduction for pseudomyxoma peritonei is optimal but maximal tumor debulking may be beneficial in patients in whom complete tumor removal cannot be achieved.
Dayal S; Taflampas P; Riss S; Chandrakumaran K; Cecil TD; Mohamed F; Moran BJ
Dis Colon Rectum; 2013 Dec; 56(12):1366-72. PubMed ID: 24201390
[TBL] [Abstract][Full Text] [Related]
9. Outcome differences between debulking surgery and cytoreductive surgery in patients with Pseudomyxoma peritonei.
Andréasson H; Graf W; Nygren P; Glimelius B; Mahteme H
Eur J Surg Oncol; 2012 Oct; 38(10):962-8. PubMed ID: 22809859
[TBL] [Abstract][Full Text] [Related]
10. Drug Sensitivity Testing in Cytoreductive Surgery and Intraperitoneal Chemotherapy of Pseudomyxoma Peritonei.
Bjersand K; Mahteme H; Sundström Poromaa I; Andréasson H; Graf W; Larsson R; Nygren P
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S810-6. PubMed ID: 26193962
[TBL] [Abstract][Full Text] [Related]
11. Outcome of patients with aggressive pseudomyxoma peritonei treated by cytoreductive surgery and intraperitoneal chemotherapy.
Arjona-Sanchez A; Muñoz-Casares FC; Casado-Adam A; Sánchez-Hidalgo JM; Ayllon Teran MD; Orti-Rodriguez R; Padial-Aguado AC; Medina-Fernández J; Ortega-Salas R; Pulido-Cortijo G; Gómez-España A; Rufián-Peña S
World J Surg; 2013 Jun; 37(6):1263-70. PubMed ID: 23532601
[TBL] [Abstract][Full Text] [Related]
12. Validation of the Recent PSOGI Pathological Classification of Pseudomyxoma Peritonei in a Single-Center Series of 265 Patients Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
Baratti D; Kusamura S; Milione M; Bruno F; Guaglio M; Deraco M
Ann Surg Oncol; 2018 Feb; 25(2):404-413. PubMed ID: 29159742
[TBL] [Abstract][Full Text] [Related]
13. Long-term survival after aggressive treatment of relapsed serosal or distant pseudomyxoma peritonei.
Delhorme JB; Honoré C; Benhaim L; Dumont F; Dartigues P; Dromain C; Ducreux M; Elias D; Goéré D
Eur J Surg Oncol; 2017 Jan; 43(1):159-167. PubMed ID: 27646440
[TBL] [Abstract][Full Text] [Related]
14. Cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei.
Güner Z; Schmidt U; Dahlke MH; Schlitt HJ; Klempnauer J; Piso P
Int J Colorectal Dis; 2005 Mar; 20(2):155-60. PubMed ID: 15503065
[TBL] [Abstract][Full Text] [Related]
15. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1000 patients with perforated appendiceal epithelial tumours.
Ansari N; Chandrakumaran K; Dayal S; Mohamed F; Cecil TD; Moran BJ
Eur J Surg Oncol; 2016 Jul; 42(7):1035-41. PubMed ID: 27132072
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of complete cytoreductive surgery and two intraperitoneal chemotherapy techniques in Pseudomyxoma peritonei.
Sørensen O; Flatmark K; Reed W; Wiig JN; Dueland S; Giercksky KE; Larsen SG
Eur J Surg Oncol; 2012 Oct; 38(10):969-76. PubMed ID: 22763244
[TBL] [Abstract][Full Text] [Related]
17. The modified Glasgow prognosis score predicts for overall and disease-free survival following cytoreductive surgery and HIPEC in patients with pseudomyxoma peritonei of appendiceal origin.
Tan GH; Novo CA; Dayal S; Chandrakumaran K; Mohamed F; Cecil T; Moran BJ
Eur J Surg Oncol; 2017 Feb; 43(2):388-394. PubMed ID: 27866811
[TBL] [Abstract][Full Text] [Related]
18. Survival of patients with pseudomyxoma peritonei treated by serial debulking.
Järvinen P; Järvinen HJ; Lepistö A
Colorectal Dis; 2010 Sep; 12(9):868-72. PubMed ID: 19519686
[TBL] [Abstract][Full Text] [Related]
19. The second procedure combining complete cytoreductive surgery and intraperitoneal chemotherapy for isolated peritoneal recurrence: postoperative course and long-term outcome.
Brouquet A; Goéré D; Lefèvre JH; Bonnet S; Dumont F; Raynard B; Elias D
Ann Surg Oncol; 2009 Oct; 16(10):2744-51. PubMed ID: 19626375
[TBL] [Abstract][Full Text] [Related]
20. Peritoneal pseudomyxoma: results of a systematic policy of complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Elias D; Honoré C; Ciuchendéa R; Billard V; Raynard B; Lo Dico R; Dromain C; Duvillard P; Goéré D
Br J Surg; 2008 Sep; 95(9):1164-71. PubMed ID: 18690633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
